Treatment of nocturnal asthma with pulsed-release albuterol.
The treatment of nocturnal asthma remains a challenge. We investigated the use of a pulsed-released albuterol in ten patients with nocturnal symptoms of asthma. In a randomized, double-blind, placebo-controlled, crossover designed study, we tested the use of 8 mg of pulsed-release albuterol sulfate (Proventil Repetabs) vs placebo. The pulsed-release albuterol significantly blunted the overnight drop in FEV1, improved peak flow readings in the morning, and decreased subjective awakenings from sleep. We conclude that pulsed-released albuterol is an effective therapeutic option in patients with nocturnal asthma.
Bogin
R M
RM
Department of Medicine, National Jewish Center for Immunology and Respiratory Medicine, Denver 80206.
Ballard
R D
RD
D000293:Adolescent; D000328:Adult; D000368:Aged; D000420:Albuterol / Q000008:administration & dosage*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D002940:Circadian Rhythm / Q000187:drug effects* / Q000502:physiology; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D004341:Drug Evaluation; D006801:Humans; D008875:Middle Aged; D012890:Sleep / Q000187:drug effects / Q000502:physiology; D013147:Spirometry
D003692:Delayed-Action Preparations; D000420:Albuterol